PERTH, Australia – Sydney-based gene therapy company Benitec Biopharma Ltd. saw its stock more than double following a global out-licensing deal with Axovant Sciences Ltd. valued at $187.5 million for its DNA-directed RNA interference (ddRNAi) therapy BB-301.
